I2S: 12% growth in the first half of 2026

I2S announced a 12% increase in its overall revenue for the first half of 2026, driven in particular by a significant 20% rebound in exports. This performance exceeded expectations and was accompanied by an increase in order books. Research and development efforts were intensified, especially in the medical device sector. Although the gross margin decreased slightly to 51%, the company anticipates improved profitability starting in 2027.

In terms of financial management, the management team successfully optimized personnel costs, which decreased by €104,000. General expenses were also reduced by 2%. Net income increased by €142,000 despite a loss of €191,000 at the end of the first half of the year. Debt is down, with a net debt-to-equity ratio of -26.2%, strengthening the company's financial health.